Ribociclib

This year’s San Antonio Breast Cancer Symposium spotlighted practice-changing research in several subtypes.

In this episode of Meeting Mic, we bring you the highlights and insights from the SABCS 2022, as well as Healio’s top headlines from the meeting.

SAN ANTONIO — First-line ribociclib plus endocrine therapy appeared associated with longer PFS and fewer adverse events than combination chemotherapy among certain patients with advanced breast cancer, according to study results.

Healio rounded up the top breast cancer coverage presented and discussed at ASCO Annual Meeting in Chicago.

CHICAGO — Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.

The addition of ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, topline data showed.

In this video, Angela DeMichele, MD, MSCE, discusses presentations from the 2021 San Antonio Breast Cancer Symposium on estrogen receptor-positive breast cancer.

In this video, Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, discusses results from the PALLAS trial assessing palbociclib in early breast cancer.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, discusses some of the highlights in hormone receptor-positive breast cancer presented at this year’s San Antonio Breast Cancer Symposium.

The addition of ribociclib to front-line letrozole prolonged OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, results of the randomized phase 3 MONALEESA-2 trial showed.